12.07.2012 - The French marine biotechnology specialist Hemarina SA has raised €6.3m to bring its first organ transplant product to market.
The company, founded in March 2007, is centred on the research and development of marine oxygen carriers for therapeutic and industrial applications. It develops extracellular haemoglobin for four core business programmes: organ transplantation and tissue conservation; blood oxygen carriers; infections and wound healing; and bio-production. The Morlaix based company is predicting to bring its first medical application product by end of 2013 in the field of kidney transplantation.
„This new round of investment shows the trust of our new partners and board members“, stated Franck Zal, CEO of Hemarina. The syndicate was led by Inserm Transfert Initiative and includes historical investors such as Finistère Angels, Armor Angels, XMP and Arkéa Capital Investissement; and also a new entrant which is a family office represented and mandated by M. Maurice Lesaffre.
Since last November, Hemarina receives research funding from the French National Research Agency (ANR) to push forward its lead candidate Hemo2Life solution for preserving kidney grafts. In a public private partnership, Hemarina will attempt to validate its oxygen carrier or the storage of kidney transplants in preservation solutions and machine perfusion systems. To do so, the French marine biotech specialist has teamed up with the INSERM U927 research unit “Ischemia-reperfusion in kidney transplantation” at the Poitiers University Hospital, and the Health, Life, and Agricultural Sciences Infrastructures (IBiSA) facility ‘Surgery, Experimentation, Transplantation’ in Surgères.
12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.